Please login to the form below

Not currently logged in
Email:
Password:

UK signals desire for close post-Brexit relationship with EU

Health and business ministers outline areas where collaboration may continue

Brexit

The UK government appears to be ready to take a more pragmatic stance on its post-Brexit approach to medicines regulation.

Writing in the Financial Times, health secretary Jeremy Hunt and business secretary Greg Clark said “the UK would like to find a way to continue to collaborate with the EU”.

Such a deal would both be “in the interests of public health and safety” and help protect the UK’s pharmaceutical industry, they added.

Although not yet official policy, it’s the clearest signal yet of the UK’s Brexit negotiating position as it concerns the pharmaceutical industry, and found praise from the sector.

ABPI chief executive Mike Thompson said: "This letter is a welcome recognition that the future of medicines regulation is a key priority for the government as we negotiate a new relationship with the EU.

"It also signals a readiness to take a pragmatic approach to Brexit negotiations that puts people’s health first. This is a great first step and we look forward to seeing more detail in the coming weeks and months.”

Regardless of the UK’s eventual pharma position, the EMA has been busy scenario planning on the assumption the country will no longer participate in its work or the European medicines regulatory system after 30 March 2019.

Before then location of the EMA after it leaves London is set to be decided in November this year, with the industry keen for a swift decision on the issue.

Article by
Dominic Tyer

4th July 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Real patient voices
The #Human behind every number project...
translational pharmacology medicine dose
The gold standard of scientific evidence
Will randomised controlled trials become a thing of the past?...
What does programmatic advertising mean for your pharma marketing strategy?
Senior Associate Consultant Jiayi Chen explains the benefits and pitfalls of programmatic advertising and reveals how it can impact return on investment in your marketing campaigns....

Infographics